Drug Trial Radar · NCT03905707
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
May 7, 2019
Primary completion
Apr 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Conditions
- Short Bowel Syndrome
Interventions
glepaglutideDrug
Glucagon-Like Peptide-2 (GLP-2) analog
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Adverse EventsTime frame: 2 years
Locations
27 sites in 9 countries. Site status is shown where the registry gives one.
Georgetown University Medical Center
Washington D.C., District of Columbia
University of Chicago Children's Hospital
Chicago, Illinois
Mayo Clinic College of Medicine
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Mount Sinai Hospital
New York, New York
Cleveland Clinic
Cleveland, Ohio
Vanderbilt University Medical Center, Nashville
Nashville, Tennessee
UZ Leuven
Leuven, Belgium
The Royal Alexandra Hospital
Edmonton, Canada
Western University
London, Canada
University Health Network - Toronto General Hospital
Toronto, Canada
Rigshospitalet
Copenhagen, Denmark
Hôpital Beaujon
Clichy, France
Centre Hospitalier Lyon-Sud
Pierre-Bénite, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Bonn
Bonn, Germany
Universitätsklinikum Frankfurt - Med. Klinik I
Frankfurt, Germany
Asklepios Kliniken Hamburg GmbH
Hamburg, Germany
Universitätsmedizin Rostock
Rostock, Germany
UMC Radboud Nijmegen
Nijmegen, Netherlands
Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi
Lodz, Poland
Solumed
Poznan, Poland
Szpital Skawina sp. z o.o. im. Stanley Dudricka
Skawina, Poland
St Mark's Hospital
Harrow, United Kingdom
UCLH Foundation NHS Trust
London, United Kingdom
University of East Anglia
Norwich, United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.